Ksenia Glumakova

Dr. Ksenia Glumakova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KGKsenia Glumakova
Ksenia Glumakova
GIGeorgy A. Ivanov
Georgy A. Ivanov
VVValeria Vedernikova
Valeria Vedernikova
LSLena Yurievna Shyrokova
Lena Yurievna Shyrokova
TLTimofey Lebedev
Timofey Lebedev
PSPavel Spirin
Pavel Spirin
Nucleoside reverse transcriptase inhibitors are the first class of drugs to be approved by the FDA for the suppression of HIV-1 and are widely used for this purpose in combination with drugs of other classes. Despite the progress in HIV-1 treatment, there is still the need to develop novel efficient antivirals. Here the efficiency of HIV-1 inhibition by a set of original 5-substituted uridine nucleosides was studied. We used the replication deficient human immunodeficiency virus (HIV-1)-based lentiviral particles and identified that among the studied compounds, 2′,3′-isopropylidene-5-iodouridine was shown to cause anti-HIV-1 activity. Importantly, no toxic action of this compound against the cells of T-cell origin was found. We determined that this compound is significantly more efficient at suppressing HIV-1 compared to Azidothymidine (AZT) when taken at the high non-toxic concentrations. We did not find any profit when using AZT in combination with 2′,3′-isopropylidene-5-iodouridine. 2′,3′-Isopropylidene-5-iodouridine acts synergistically to repress HIV-1 when combined with the CDK4/6 inhibitor Palbociclib in low non-toxic concentration. No synergistic antiviral action was detected when AZT was combined with Palbociclib. We suggest 2′,3′-isopropylidene-5-iodouridine as a novel perspective non-toxic compound that may be used for HIV-l suppression.

25 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PSPavel Spirin
Pavel Spirin
VVValeria Vedernikova
Valeria Vedernikova
TVTatsiana Volkava
Tatsiana Volkava
AMAlexey Morozov
Alexey Morozov
AKAlla V Kleymenova
Alla V Kleymenova
VPVladimir S. Prassolov
Vladimir S. Prassolov
Background: Histone deacetylases (HDACs) are critical epigenetic modulators involved in regulating various molecular mechanisms essential for cell development and growth. Alterations in HDAC activity have been linked to the progression of numerous cancers, including lymphoma. Over the past decade, the FDA has approved several HDAC inhibitors for lymphoma treatment, leading to heightened interest in this emerging class of drugs. Methods: In our research, we developed a novel HDAC inhibitor that exhibits high selectivity for class I HDACs. Results: Our in vitro findings indicate that treating lymphoma/leukemia cells with this inhibitor results in a marked suppression of cell growth and promotes apoptosis, while leaving the cell cycle unaffected. Conclusions: We propose that our new inhibitor, named eimbinostat, holds significant promise as a potential therapeutic agent for the treatment of hematologic malignancies such as lymphoma or leukemia.

21 October 2026 in European Journal of Inorganic Chemistry
Verified
Journal Article
Open access
PDF file
EAElina Antonova
Elina Antonova
ARAndrey S. Romanov
Andrey S. Romanov
SKSvetlana A. Katkova
Svetlana A. Katkova
KIKarina A. Ivanenko
Karina A. Ivanenko
MBMikhail A. Bogomolov
Mikhail A. Bogomolov
MKMikhail Kinzhalov
Mikhail Kinzhalov
Two series of C^N‐cyclometalated platinum(II) complexes bearing acyclic diaminocarbene (ADC) ligands were synthesized via the nucleophilic addition of diethylamine to cycloplatinated isocyanide precursors. The complexes exhibit intense phosphorescence, with Φ PL up to 75%, as well as remarkable hydrolytic stability. The ADC complexes display potent antiproliferative activity against a panel of solid and hematological cancer cell lines, with IC 50 values ranging from 0.5 to 4.4 µM. Leukemia cells were the most sensitive, with IC 50 values of 0.5–1.0 µM. Unlike cisplatin and oxaliplatin, which act mainly as cytostatic agents, the complexes induce rapid cytotoxic effects within 12 h. The m ‐CF 3 ‐substituted derivatives showed higher activity than their p ‐CF 3 analogs, highlighting the potential of these complexes as promising anticancer metallodrugs.